References
- Ahmad F, Mandava S, Das BR (2010). Analysis of FLT3-ITD and FLT3-Asp835 mutations in de novo acute myeloid leukemia: evaluation of incidence, distribution pattern, correlation with cytogenetics and characterization of internal tandem duplication from Indian population. Cancer Invest, 28, 63-73. https://doi.org/10.3109/07357900903095649
- Annesley CE, Brown P (2014). The biology and targeting of FLT3 in pediatric leukemia. Front Oncol, 4, 263.
- Auewarakul CU, Sritana N, Limwongse C, et al (2005). Mutations of the FLT3 gene in adult acute myeloid leukemia: determination of incidence and identification of a novel mutation in a Thai population. Cancer Genet Cytogenet, 162, 127-34. https://doi.org/10.1016/j.cancergencyto.2005.03.011
- Bacher U, Schnittger S, Haferlach T (2010). Molecular genetics in acute myeloid leukemia. Curr Opin Oncol, 22, 646-55. https://doi.org/10.1097/CCO.0b013e32833ed806
- Elyamany G, Awad M, Fadalla K, et al (2014). Frequency and Prognostic Relevance of FLT3 Mutations in Saudi Acute Myeloid Leukemia Patients. Adv Hematol, 2014, 141360.
- Estey EH (2013). Acute myeloid leukemia: 2013 update on riskstratification and management. Am J Hematol, 88, 318-27.
- Gilliland DG, Griffin JD (2002). The roles of FLT3 in hematopoiesis and leukemia. Blood, 100, 1532-42. https://doi.org/10.1182/blood-2002-02-0492
- Ishfaq M, Malik A, Faiz M, et al (2012). Molecular characterization of FLT3 mutations in acute leukemia patients in Pakistan. Asian Pac J Cancer Prev, 13, 4581-5. https://doi.org/10.7314/APJCP.2012.13.9.4581
- Kainz B, Heintel D, Marculescu R, et al (2002). Variable prognostic value of FLT3 internal tandem duplications in patients with de novo AML and a normal karyotype, t(15;17), t(8;21) or inv(16). Hematol J, 3, 283-9. https://doi.org/10.1038/sj.thj.6200196
- Kayser S, Schlenk RF, Londono MC, et al (2009). Insertion of FLT3 internal tandem duplication in the tyrosine kinase domain-1 is associated with resistance to chemotherapy and inferior outcome. Blood, 114, 2386-92. https://doi.org/10.1182/blood-2009-03-209999
- Kindler T, Lipka DB, Fischer T (2010). FLT3 as a therapeutic target in AML: still challenging after all these years. Blood, 116, 5089-102. https://doi.org/10.1182/blood-2010-04-261867
- Kiyoi H, Naoe T, Yokota S, et al (1997). Internal tandem duplication of FLT3 associated with leukocytosis in acute promyelocytic leukemia. leukemia study group of the Ministry of Health and Welfare (Kohseisho). Leukemia, 11, 1447-52. https://doi.org/10.1038/sj.leu.2400756
- Kottaridis PD, Gale RE, Frew ME, et al (2001). The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the United Kingdom Medical Research Council AML 10 and 12 trials. Blood, 98, 1752-9. https://doi.org/10.1182/blood.V98.6.1752
- Levis M (2013). FLT3 mutations in acute myeloid leukemia: what is the best approach in 2013? Hematol Am Soc Hematol Educ Program, 2013, 220-6.
- Louicharoen C, Nuchprayoon I (2005). G6PD Viangchan (871G>A) is the most common G6PD-deficient variant in the Cambodian population. J Hum Genet, 50, 448-52. https://doi.org/10.1007/s10038-005-0276-2
- Meshinchi S, Alonzo TA, Stirewalt DL, et al (2006). Clinical implications of FLT3 mutations in pediatric AML. Blood, 108, 3654-61. https://doi.org/10.1182/blood-2006-03-009233
- Molica M, Breccia M (2015). FLT3-ITD in acute promyelocytic leukemia: clinical distinct profile but still controversial prognosis. Leuk Res, 39, 397-9. https://doi.org/10.1016/j.leukres.2015.01.004
- Moreno I, Martin G, Bolufer P, et al (2003). Incidence and prognostic value of FLT3 internal tandem duplication and D835 mutations in acute myeloid leukemia. Haematologica, 88, 19-24.
- Mukda E, Pintaraks K, Sawangpanich R, et al (2011). FLT3 and NPM1 gene mutations in childhood acute myeloblastic leukemia. Asian Pac J Cancer Prev, 12, 1827-31.
- Noguera NI, Breccia M, Divona M, et al (2002). Alterations of the FLT3 gene in acute promyelocytic leukemia: association with diagnostic characteristics and analysis of clinical outcome in patients treated with the Italian AIDA protocol. Leukemia, 16, 2185-9. https://doi.org/10.1038/sj.leu.2402723
- Nuchprayoon I, Sanpavat S, Nuchprayoon S (2002). Glucose-6-phosphate dehydrogenase (G6PD) mutations in Thailand: G6PD Viangchan (871G>A) is the most common deficiency variant in the Thai population. Hum Mutat, 19, 185.
- Poire X, Moser BK, Gallagher RE, et al (2014). Arsenic trioxide in front-line therapy of acute promyelocytic leukemia (C9710): prognostic significance of FLT3 mutations and complex karyotype. Leuk Lymphoma, 55, 1523-32. https://doi.org/10.3109/10428194.2013.842985
- Port M, Bottcher M, Thol F, et al (2014). Prognostic significance of FLT3 internal tandem duplication, nucleophosmin 1, and CEBPA gene mutations for acute myeloid leukemia patients with normal karyotype and younger than 60 years: a systematic review and meta-analysis. Ann Hematol, 93, 1279-86. https://doi.org/10.1007/s00277-014-2072-6
- Pui CH, Carroll WL, Meshinchi S, et al (2011). Biology, risk stratification, and therapy of pediatric acute leukemias: an update. J Clin Oncol, 29, 551-65.
- Schnittger S, Schoch C, Dugas M, et al (2002). Analysis of FLT3 length mutations in 1003 patients with acute myeloid leukemia: correlation to cytogenetics, FAB subtype, and prognosis in the AMLCG study and usefulness as a marker for the detection of minimal residual disease. Blood, 100, 59-66. https://doi.org/10.1182/blood.V100.1.59
- Small D (2006). FLT3 mutations: biology and treatment. Hematology Am Soc Hematol Educ Program, 178-84.
- Stirewalt DL, Kopecky KJ, Meshinchi S, et al (2006). Size of FLT3 internal tandem duplication has prognostic significance in patients with acute myeloid leukemia. Blood, 107, 3724-6. https://doi.org/10.1182/blood-2005-08-3453
- Stirewalt DL, Radich JP (2003). The role of FLT3 in haematopoietic malignancies. Nat Rev Cancer, 3, 650-65. https://doi.org/10.1038/nrc1169
- Suzuki R, Onizuka M, Kojima M, et al (2007). Prognostic significance of FLT3 internal tandem duplication and NPM1 mutations in acute myeloid leukemia in an unselected patient population. Int J Hematol, 86, 422-8. https://doi.org/10.1007/BF02984000
- Thai Pediatric Oncology Group (2014). Treatment protocol for childhood cancer 2014., Bangkok, Imprint corporation.
- Thiede C, Steudel C, Mohr B, et al (2002). Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis. Blood, 99, 4326-35. https://doi.org/10.1182/blood.V99.12.4326
- Vempati S, Reindl C, Kaza SK, et al (2007). Arginine 595 is duplicated in patients with acute leukemias carrying internal tandem duplications of FLT3 and modulates its transforming potential. Blood, 110, 686-94. https://doi.org/10.1182/blood-2006-10-053181
- Weisberg E, Barrett R, Liu Q, et al (2009). FLT3 inhibition and mechanisms of drug resistance in mutant FLT3-positive AML. Drug Resist Updat, 12, 81-9. https://doi.org/10.1016/j.drup.2009.04.001
- Wiernik PH (2010). FLT3 inhibitors for the treatment of acute myeloid leukemia. Clin Adv Hematol Oncol, 8, 429-36, 44.
- Xu YY, Gao L, Ding Y, et al (2012). [Detection and clinical significance of FLT3-ITD gene mutation in patients with acute myeloid leukemia]. Zhongguo Shi Yan Xue Ye Xue Za Zhi, 20, 1312-5.
- Yohe S (2015). Molecular Genetic Markers in Acute Myeloid Leukemia. J Clin Med, 4, 460-78. https://doi.org/10.3390/jcm4030460
- Yunus NM, Johan MF, Ali Nagi Al-Jamal H, et al (2015). Characterisation and clinical significance of FLT3-ITD and non-ITD in acute myeloid leukaemia patients in Kelantan, Northeast Peninsular Malaysia. Asian Pac J Cancer Prev, 16, 4869-72. https://doi.org/10.7314/APJCP.2015.16.12.4869
- Zwaan CM, Meshinchi S, Radich JP, et al (2003). FLT3 internal tandem duplication in 234 children with acute myeloid leukemia: prognostic significance and relation to cellular drug resistance. Blood, 102, 2387-94. https://doi.org/10.1182/blood-2002-12-3627